MicroRNA 4279 (miR-4279)

MicroRNA 4279 (miR-4279, hsa-mir-4279) is a member of the microRNA (miRNA) family, which are small, single-stranded, non-coding RNA molecules (~21–23 nucleotides) involved in post-transcriptional gene regulation. miRNAs base-pair with target messenger RNAs (mRNAs) and either degrade the mRNA or inhibit its translation. This process, termed RNA interference, helps regulate gene expression in diverse cellular pathways and plays critical roles in cellular differentiation, proliferation, development, and disease[1][2][5]. Most miRNAs, including miR-4279, have not been validated as therapeutic targets, drug targets, or direct disease drivers. Public data do not detail any miR-4279-specific biological activity, disease relevance, or drug interactions—unlike well-characterized miRNAs (e.g., miR-21, miR-155). Notes on correctness and target status: - There is no evidence of "microRNA 4279" or "MIR4279" being a validated therapeutic target, disease driver, or actionable biomarker in the literature[1][2][3][4][5]. - Current scientific and clinical resources do not describe miR-4279 as a bona fide disease-associated miRNA, and it is not tracked in standard drug or disease targeting databases. - This entry appears to be a less characterized or predicted microRNA locus with little or no functional annotation or experimental validation. Thus, it should not be treated as an established target or therapeutic receptor of interest. Summary of why "is_target" is false and "is_incorrect" is true: - There is insufficient published evidence that miR-4279 is an actionable or experimentally validated therapeutic target. - No disease or pharmacological context is available for miR-4279. - This name may refer to a predicted or uncharacterized miRNA, and may lack experimental support.

Other names

hsa-mir-4279miR-4279MIR4279

miRNAs in general act by binding to complementary sequences in mRNA targets to downregulate gene expression via mRNA cleavage or translational repression[1].